Literature DB >> 14662840

Phosphodiesterase 7A-deficient mice have functional T cells.

Guchen Yang1, Kim W McIntyre, Robert M Townsend, Henry H Shen, William J Pitts, John H Dodd, Steven G Nadler, Murray McKinnon, Andrew J Watson.   

Abstract

Phosphodiesterases (PDEs) are enzymes which hydrolyze the cyclic nucleotide second messengers, cAMP and cGMP. In leukocytes, PDEs are responsible for depletion of cAMP which broadly suppresses cell functions and cellular responses to many activation stimuli. PDE7A has been proposed to be essential for T lymphocyte activation based on its induction during cell activation and the suppression of proliferation and IL-2 production observed following inhibition of PDE7A expression using a PDE7A antisense oligonucleotide. These observations have led to the suggestion that selective PDE7 inhibitors could be useful in the treatment of T cell-mediated autoimmune diseases. In the present report, we have used targeted gene disruption to examine the role PDE7A plays in T cell activation. In our studies, PDE7A knockout mice (PDE7A(-/-)) showed no deficiencies in T cell proliferation or Th1- and Th2-cytokine production driven by CD3 and CD28 costimulation. Unexpectedly, the Ab response to the T cell-dependent Ag, keyhole limpet hemocyanin, in the PDE7A(-/-) mice was found to be significantly elevated. The results from our studies strongly support the notion that PDE7A is not essential for T cell activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662840     DOI: 10.4049/jimmunol.171.12.6414

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  Combined use of pharmacophoric models together with drug metabolism and genotoxicity "in silico" studies in the hit finding process.

Authors:  Ma José Jerez; Miguel Jerez; Coral González-García; Sara Ballester; Ana Castro
Journal:  J Comput Aided Mol Des       Date:  2013-01-08       Impact factor: 3.686

4.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline.

Authors:  Philip L De Jager; Joshua M Shulman; Lori B Chibnik; Brendan T Keenan; Towfique Raj; Robert S Wilson; Lei Yu; Sue E Leurgans; Dong Tran; Cristin Aubin; Christopher D Anderson; Alessandro Biffi; Jason J Corneveaux; Matthew J Huentelman; Jonathan Rosand; Mark J Daly; Amanda J Myers; Eric M Reiman; David A Bennett; Denis A Evans
Journal:  Neurobiol Aging       Date:  2011-11-04       Impact factor: 4.673

Review 5.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 6.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

7.  PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury.

Authors:  Irene Paterniti; Emanuela Mazzon; Carmen Gil; Daniela Impellizzeri; Valle Palomo; Myriam Redondo; Daniel I Perez; Emanuela Esposito; Ana Martinez; Salvatore Cuzzocrea
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

Review 8.  ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors:  David M G Halpin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

9.  Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors.

Authors:  Tania Castaño; Huanchen Wang; Nuria E Campillo; Sara Ballester; Coral González-García; Javier Hernández; Concepción Pérez; Jimena Cuenca; Ana Pérez-Castillo; Ana Martínez; Oscar Huertas; José Luis Gelpí; F Javier Luque; Hengming Ke; Carmen Gil
Journal:  ChemMedChem       Date:  2009-05       Impact factor: 3.466

Review 10.  Emerging themes from EBV and KSHV microRNA targets.

Authors:  Dhivya Ramalingam; Philippe Kieffer-Kwon; Joseph M Ziegelbauer
Journal:  Viruses       Date:  2012-09-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.